Published in Elder Law Weekly, April 13th, 2005
The phase I clinical trial is the first of a planned series of studies examining the safety and pharmacokinetics of PBT2 in normal human volunteers.
PBT2 is the first completely Prana-discovered compound, and is the successor to PBT1 for the treatment of Alzheimer disease. PBT2 is designed to have an improved safety and efficacy profile compared to PBT1. The compound has demonstrated significantly greater...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.